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Background: Patients with left ventricular systolic dysfunction (LVSD) are at high risk of sudden cardiac death (SCD). Implantable cardioverter 
defibrillators (ICDs) have an important role in preventing SCD in selected patients with LVSD & chronic heart failure (CHF). Drug therapies for LVSD & 
CHF also appear to also be useful in reducing SCD. However, the magnitude of benefit on SCD is uncertain. We therefore conducted a meta-analysis 
comparing the effect on SCD achieved by ICDs vs newer medical therapies, additional to standard background medical therapies i.e. ACE inhibitors 
and beta-blockers (BBs).
Methods: Our meta-analysis included trials of > 100 patients with low left ventricular ejection fraction (LVEF) i.e. <40%. Sixteen randomised 
controlled trials met criteria for meta-analysis, 11 involving newer medical therapies (ARBs, mineralocorticoid receptor antagonists [MRAs], 
ivabradine, n3-PUFA, ferric carboxymaltose) and 5 involving ICDs. Results were pooled using the Mantel-Haenzsel method.
Results: Drug therapy (n=40,034) did not significantly reduce risk of SCD overall (risk ratio 0.92, 95% confidence interval 0.83-1.02, p =0.11) 
when compared to placebo, however when post-myocardial infarction studies were excluded, drug therapy resulted in a statistically significant 
reduction in SCD (RR 0.91 [0.83, 0.99], p=0.02). Of the different drug classes, MRAs were particularly effective, (n = 11,032, RR 0.79 [0.68, 0.91], 
p = 0.001). ICD insertion (n=4,372) greatly reduced SCD (RR 0.40 [0.31, 0.51], p < 0.00001) compared with placebo. The difference between ICD 
and drug therapy on SCD was significant (0.47 [95% CI 0.38, 0.58] p < 0.001); differences between ICD and MRAs on SCD were also significant 
(0.66 [95% CI 0.52, 0.89] p < 0.001.
Conclusions: Newer drug therapies, especially MRAs, appear to be effective agents in reducing SCD in the LVSD setting but not in the post-
myocardial infarction setting. ICDs were even more effective than drugs in SCD abrogation. The added procedural morbidity and cost of ICD needs to 
be considered in decision-making re approach to SCD reduction in the individual patient.
